

Table 1. *EGFR* pathway mutations in tissue samples from patients with mCRC treated with cetuximab

| Patient # | Pre-treatment | | | | | | | | | | | Post-treatment | | | | | | | | | | | | | |
|-----------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|---------------------|----------------------|-----------------------|---------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|---------------------|----------------------|-----------------------|---------------------|-------|-------|-------|-------|-------|
| | <i>KRAS</i> exon 2 | <i>KRAS</i> exon 3 | <i>KRAS</i> exon 4 | <i>NRAS</i> exon 2 | <i>NRAS</i> exon 3 | <i>NRAS</i> exon 4 | <i>BRAF</i> exon 15 | <i>PIK3CA</i> exon 9 | <i>PIK3CA</i> exon 20 | <i>EGFR</i> exon 12 | <i>KRAS</i> exon 2 | <i>KRAS</i> exon 3 | <i>KRAS</i> exon 4 | <i>NRAS</i> exon 2 | <i>NRAS</i> exon 3 | <i>NRAS</i> exon 4 | <i>BRAF</i> exon 15 | <i>PIK3CA</i> exon 9 | <i>PIK3CA</i> exon 20 | <i>EGFR</i> exon 12 | | | | | |
| | | | | | | | | | | | | | | | | | | | | R451C | S464L | G465R | K467T | I491M | S492R |
| 4 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 5 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 8 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 11 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 13 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 15 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 16 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 17 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 18 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 20 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 21 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 23 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 26 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 27 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 31 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 33 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 34 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 35 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 36 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 37 | | | | | | | | | | | | | | | | | | | | | | | | | |

NOTE: *KRAS*, *NRAS*, *BRAF*, *PIK3CA*, and *EGFR* mutations were analyzed in paired tissue samples obtained at diagnosis (pre-treatment) and at progression (post-treatment). Black boxes indicate the presence of mutations detected by clinical routine sequencing procedures.

mutations). Of note, mutations in *PIK3CA* always coexisted with other mutations within the same sample.

Notably, in addition to "RAS" gene mutations the molecular analysis revealed the emergence of multiple alleles in the *EGFR* extracellular domain. The previously reported *EGFR* S492R variant was detected in 3 patients. Of note, *EGFR* mutations were accompanied by gene amplification in both the pre- and the posttreatment specimen from two of these patients (data not shown); in the third patient, *EGFR* gene copy number was not assessed due to lack of sufficient tissue for FISH analysis.

Two novel mutations located in exon 12 of the *EGFR* gene were discovered by the analysis of posttreatment samples. Patient #31 harbored an A → C substitution at codon 1400 that caused a substitution of a lysine to threonine at amino acid 467 (p.K467T). The postcetuximab biopsy from patient #35 harbored a C → T substitution at codon 1351, resulting in an arginine to cysteine substitution at amino acid 451 (p.R451C; Table 1; Supplementary Fig. S1).

EGFR ectodomain mutations and acquired resistance to cetuximab in colorectal cancer cell models

We previously reported that acquisition of resistance in colorectal cancer cells is associated with emergence of *KRAS*-, *BRAF*-, and *NRAS*-activating mutations (6, 9, 12). To discover additional mechanisms of resistance to *EGFR* blockade, we exploited 5 colorectal cancer cell lines (DiFi, LIM1215, HCA-46, NCIH508, OXCO-2, and CCK81), which are highly sensitive to cetuximab (Supplementary Fig. S2). These cell lines are wild-type for *KRAS*, *NRAS*, *BRAF*, and *PIK3CA* with the exception of NCIH508, which displays the p.E545K *PIK3CA* mutation. Altogether, these cell

models recapitulate the molecular features of tumors from patients with colorectal cancer likely to respond to anti *EGFR* therapies. For each line, at least five million cells were exposed continuously to cetuximab until resistant populations emerged (Supplementary Fig. S2). To define molecular mechanisms underlying acquisition of resistance, we initially performed Sanger sequencing of genes involved in regulation of the *EGFR* signaling pathway (*EGFR*, *KRAS*, *BRAF*, *NRAS*, and *PIK3CA*). In accordance with our previous reports, resistant populations often displayed *KRAS*, *BRAF*, and *NRAS* mutations (Table 2; ref. 9). All of these alleles were detected in the resistant cells but not in the corresponding parental population from which they originated. Importantly, in several occasions multiple genetic alterations were concomitantly present in the resistant cell population (Table 2) indicating their polyclonal status. To assess the molecular features of individual clones, we performed limited cell dilutions of LIM1215 and CCK81 as these cell lines are amenable to this procedure. We then subjected single clones to Sanger sequencing for candidate genes (*EGFR*, *KRAS*, *BRAF*, *NRAS*, and *PIK3CA*). Notably, mutation profiling of clones identified three novel *EGFR* variants: S464L, G465R, and I491M (Supplementary Fig. S3). Considering that the resistant derivatives are polyclonal, and in light of the limited sensitivity of the Sanger sequencing method, we postulated that variants present in less than 20% of the cell populations might have remained undetected. To identify mutations present at low frequency, we employed ddPCR, which is known to have a mutant/wild-type sensitivity of 1:20,000. ddPCR probes were designed and individually validated using control mutant DNA to detect *EGFR* variants previously identified in tumor biopsy or cell lines (Supplementary Table S2). This analysis

Table 2. EGFR pathway mutations in parental and cetuximab-resistant cell lines

| Parental cell Lines | Pre-treatment | | | | | | | | | Post-treatment | | | | | | | | | | | | | | | | | | |
|---------------------|---------------|-------------|-------------|-------------|-------------|-------------|--------------|---------------|----------------|----------------|----------------------|-------------|-------------|-------------|-------------|-------------|-------------|--------------|---------------|----------------|--------------|--|--|--|--|--|--|--|
| | KRAS exon 2 | KRAS exon 3 | KRAS exon 4 | NRAS exon 2 | NRAS exon 3 | NRAS exon 4 | BRAF exon 15 | PIK3CA exon 9 | PIK3CA exon 20 | EGFR exon 12 | Resistant cell Lines | KRAS exon 2 | KRAS exon 3 | KRAS exon 4 | NRAS exon 2 | NRAS exon 3 | NRAS exon 4 | BRAF exon 15 | PIK3CA exon 9 | PIK3CA exon 20 | EGFR exon 12 | | | | | | | |
| | R451C | S464L | G465R | K467T | I491M | S492R | | | | | | | | | | | | | | | | | | | | | | |
| CCK81 | | | | | | | | | | | CCK81 R1 Cetux | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | CCK81 R2 Cetux | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | CCK81 R3 Cetux | | | | | | | | | | | | | | | | | |
| DiFi | | | | | | | | | | | DiFi R1 Cetux | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | DiFi R2 Cetux | | | | | | | | | | | | | | | | | |
| HCA-46 | | | | | | | | | | | HCA-46 R1 Cetux | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | HCA-46 R2 Cetux | | | | | | | | | | | | | | | | | |
| LIM1215 | | | | | | | | | | | LIM1215 R1 Cetux | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | LIM1215 R2 Cetux | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | LIM1215 R3 Cetux | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | LIM1215 R4 Cetux | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | LIM1215 R5 Cetux | | | | | | | | | | | | | | | | | |
| NCIH508 | | | | | | | | | | | NCIH508 R1 Cetux | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | NCIH508 R2 Cetux | | | | | | | | | | | | | | | | | |
| OXCO-2 | | | | | | | | | | | OXCO-2 R1 Cetux | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | OXCO-2 R2 Cetux | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | OXCO-2 R3 Cetux | | | | | | | | | | | | | | | | | |

NOTE: Parental and correspondent cetuximab-resistant derivatives of DiFi, LIM1215, HCA-46, NCIH508, OXCO-2, and CCK81 cell lines were analyzed for KRAS, NRAS, BRAF, PIK3CA, and EGFR mutations. Black boxes indicate the presence of the mutations (no specified alleles); in resistant cell lines, mutational analysis for EGFR exon 12 was performed by ddPCR and black boxes indicate which EGFR ectodomain alleles emerged.

Abbreviation: Cetux, cetuximab.

unveiled the presence 3 new EGFR variants (S464L, G465R, and I491M) that were not detected by Sanger sequencing in resistant cell populations (Table 2 and Supplementary Table S3). The ddPCR approach could not be performed in tissue samples, as there was no sufficient material available. Overall, the mutational landscape of cell lines with acquired resistance to cetuximab recapitulates the molecular profiles of tumors that relapsed upon cetuximab treatment.

Structural model analysis of EGFR ectodomain mutations

To understand how the EGFR ectodomain mutations detected in tumor samples and cell lines could drive resistance to EGFR blockade, we performed computational structure-based analyses. With the exception of R451C, the EGFR mutations are located in the receptor region, which has been shown to interact with cetuximab (Fig. 1A). More specifically, the S464L, G465R, K467T, I491M, and S492R mutations lie in the middle of the surface recognized by the antibody (Fig. 1B) and therefore modifications of this interface have the potential to affect complex formation. Of these five mutations, three appear to disrupt favorable interactions, namely S464L, K467T, and I491M. The polar amino acid S464 is within H-bond distance from the carbonyl backbone of Y102 and the phenolic OH-group of Y104 (Fig. 1C). Replacement by a hydrophobic bulky amino acid as leucine (S464L) has the potential to disrupt the network. Analogously, the positively charged amino acid K467 is involved in a stabilizing salt bridge with E58 (Fig. 1C). Insertion of a polar but neutral amino acid as threonine K467T, although still permitting the H-bond E58, would affect the favorable electrostatic interaction. Residue I491 is a rather large, aliphatic residue located in a hydrophobic cavity mainly formed by aromatic amino acids (Fig. 1C). Although the side chains present similar size, methio-


nine (I491M) is a polar amino acid and would be unfavorably located in a nonpolar environment. The other two mutations (G465R and S492R) involve the change from rather small, polar, and uncharged side chain to a large and electrically charged side chain in arginine (Fig. 1C; ref. 13).

R451C is the only mutation not located in the cetuximab-binding site; however, the mutation could lead to critical structural changes. As the domain IV is formed by a sequence of disulphide bonds, which preserve its tertiary structure, the replacement by a cysteine at that position could perturb one of the disulphide bonds in domain III (C475-C462) possibly forming a new one between domains III and IV (C451-C475). We verified that the distance in the crystal structure between these residues (C451-C475, carbon alpha distance 6.8 Å) is compatible with the formation of a disulphide bond. Indeed, a system setup in this new configuration successfully minimizes to a C451-C475 distance of 5.2 Å. Overall, all identified mutations in EGFR (except R451C) were located in the cetuximab-binding epitope.

Biochemical and functional analyses of EGFR ectodomain mutations

To experimentally assess the impact of the EGFR ectodomain mutations on the ability of the receptor to interact with cetuximab, we performed forward genetic experiments on the newly discovered mutations. Wild-type and mutant EGFR cDNAs were ectopically expressed in NIH 3T3 cells that lack endogenous EGFR. Flow cytometry was used to establish the extent of cetuximab binding to cells expressing the mutants; wild-type EGFR and S492R served as positive and negative controls, respectively. These experiments clearly showed that the newly discovered EGFR K467T, R451C, S464L, G465R, and I491M mutations were not permissive for binding to cetuximab thus providing functional

Arena et al.

**Figure 1.**

Structural analysis of EGFR extracellular domain mutants. A, general overview of the EGFR extracellular domain (sEGFR) bound to the antigen-binding fragment of cetuximab (cetux) as crystallized by Li and colleagues. Four subdomains comprise the sEGFR domain, and domain III contains the six mutations. Mutation R451C occurs at the interface of contact with domain IV. B, mutations I491M, S492R, S464L, G465R, and K467T are located at the surface recognized by cetuximab. A selection of residues located within 5 Å of the site of each mutation are shown. C, S464 (indicated in red, top left) is surrounded by tyrosine residues (Y102 and Y104) which favor an H-bond network. G465 (indicated in red, top right) lies in a highly hydrophobic groove formed by Y104, W54 and W52, K467 (indicated in red, central left) defines a salt bridge with E58. I491 (indicated in red, central right) is located in a hydrophobic environment formed by Q91, Y50, and Y104. S492 (indicated in red, bottom left) is located in an uncharged cavity formed by Y104, W94, P95, T98, and N91. R451 (indicated in red, bottom right) is not located at the cetuximab-sEGFR interface, but closer to the IV domain. Replacement by a cysteine could form a new disulphide bond between domain III and IV.

evidence of their role in driving acquired resistance to EGFR blockade. Of note, the effect of *EGFR* R451C on cetuximab binding was less prominent compared with the other mutants (Fig. 2).

To further characterize the functional properties of the EGFR mutations we performed biochemical studies in cells expressing individual mutations. As expected, cetuximab abrogated ligand-mediated activation of the wild-type receptor, while had no or very limited impact in cells carrying mutated EGFR (S464L, G465R, K467T, I491M, and S492R; Fig. 3). Notably, in R451C-mutant cells, cetuximab was still capable of inhibiting EGFR phosphorylation (Fig. 3).


We then examined whether panitumumab, the other anti-EGFR drug approved to treat colorectal cancer, was active in cells overexpressing EGFR mutations. As previously described, S492R-mutant cells efficiently bound to panitumumab (12). We found that the K467T and R451C mutants were to some extent permissive for panitumumab binding, whereas S464L, G465R, and I491M mutants did not bind to this antibody (Fig. 2). Accordingly, biochemical analyses showed that panitumumab prevents EGFR activation in S492R, K467, and R451C mutants (Fig. 3).

Discussion

We present a comprehensive analysis of mutational changes affecting key members of the EGFR signaling pathway emerging in tumor biopsies of patients treated with cetuximab and in cell models, which acquired resistance to cetuximab *in vitro*. We found that colorectal cancer cells evade EGFR blockade through two main strategies. The main mechanism of resistance involves downstream

pathway reactivation that occurs in 43% of patients' samples and 58.8% of the cells, respectively. The second entails EGFR extracellular domain mutations that were detected in 10.8% of patients' samples and 29% of the cells. Although the specific mutations partially differ among cell lines and patients, they overlap in terms of activated cellular pathways observed in preclinical models and patients samples (22). The cell-based findings may be translated back into the clinic. For example, the EGFR ectodomain alleles, initially discovered in cells, might reasonably also be present in patients who relapse upon EGFR blockade and this could be verified using tissue and liquid biopsies.

The molecular landscape of acquired resistance to EGFR blockade revealed the emergence of multiple point mutations in the ectodomain of EGFR. In particular, we detected two novel EGFR exon 12 mutations (EGFR p.R451C and p.K467T) in 2 patients. The previously reported *EGFR* S492R mutation was detected in 3 of 37 postcetuximab tissue samples (8%), whereas a recent study reports 16% of S492R EGFR mutation detection in 239 postcetuximab plasma samples (11). Such differences may be explained by different sensitivity of the detection techniques as well as the ability of plasma samples to capture the heterogeneity of solid tumors as compared with single biopsies of one tumoral lesion (8, 16, 23). Plasma samples of the patients included in the current study were not systematically collected and therefore we could not analyze the prevalence of EGFR mutations in circulating tumor DNA in the cohort. Accordingly, studies in larger cohorts of patients treated with cetuximab or panitumumab are warranted to define the exact frequency of the other newly identified EGFR ectodomain mutations. Of note, most samples harboring the

**Figure 2.**

EGFR mutations differentially affect binding to cetuximab and panitumumab. A, NIH 3T3 cells stably expressing wild-type or the indicated EGFR mutations were incubated with cetuximab or panitumumab, and antibody binding was analyzed by flow cytometry using a secondary antibody to human IgG conjugated with phycoerythrin (PE). NIH 3T3 cells expressing the empty vector were used as a negative control (empty). Graphs show results of one representative experiment. B, the percentage of cells binding to the antibody are shown as relative values compared to EGFR wild-type (wt) cells (percentage of EGFR wt cells set to 1) and are mean values of two independent experiments. While cetuximab binding was affected in cells expressing EGFR mutants, panitumumab was able to bind to cells expressing the S492R and K467T EGFR mutation. The R451C mutation had a moderate impact on binding to either cetuximab or panitumumab.

EGFR S492R mutation also exhibited EGFR gene amplification (12), similar to lung cancer tumors harboring the T790M mutation of resistance to tyrosine kinase inhibitors, where the T790M allele appears to be selectively amplified (24). Interestingly, our *in vitro* analysis showed that panitumumab was effective in a subset of EGFR mutants. As the binding epitopes of cetuximab and panitumumab overlap but are not identical, it is foreseeable that mutations arising in EGFR after anti-EGFR treatment will differentially disrupt binding of cetuximab and/or panitumumab to the receptor (25), with relevant clinical implications for the treatment of cetuximab-resistant patients.

Activating mutations in EGFR downstream signaling effectors were the most frequent event in both cell models and patients. Emergence of KRAS and NRAS mutations occurred in 42% of patients, similar to what we have previously reported in tissue samples, but lower than previously reported in plasma samples (6–10). Again, this may be due to the advantage of circulating

DNA in capturing the heterogeneity of solid tumors compared with biopsy of one tumoral lesion (8, 16, 23), indicating that diagnostic tools such as liquid biopsies are required to capture the complexity of the disease. As recently reported, RAS mutations often occurred outside of exon 2 in clinical samples and cell models (26, 27). The finding that codon 61 and 146 KRAS mutations occur more frequently in the acquired resistance setting than in the general colorectal cancer population is worth further studies. Of note, all samples harboring a PIK3CA mutation also displayed other mechanisms of resistance. The role of PIK3CA mutations in driving acquired as well as primary resistance remains controversial and needs to be further characterized. We did not identify emergence of molecular alterations in 20% of patients, suggesting limitations in the sensitivity of the detection technique, tumor heterogeneity, as well as other mechanisms of resistance such as ligand overexpression or c-MET amplification (15, 28, 29).

Arena et al.




Figure 3. Ligand-dependent activation of EGFR mutants in the presence of cetuximab and panitumumab. NIH 3T3 cells expressing WT *EGFR* or the indicated *EGFR* mutations were cultured in the presence of cetuximab (Ctx) or panitumumab (Pnm) for 2 hours and stimulated with EGF (5 ng/mL) for 15 minutes. Immunoblotting was performed using antibodies to the indicated proteins.

Importantly, multiple mechanisms of resistance were often present in the samples from relapsed tumors and often displayed more than one molecular alteration. This was also observed in cell lines resistant to cetuximab, strongly suggesting their polyclonal status. This likely reflects the heterogeneity of colorectal cancers and supports the role of circulating DNA to comprehensively characterize the molecular landscape of resistance to EGFR blockade in patients. Activation of EGFR-RAS signaling axis as well as EGFR ectodomain mutations frequently co-occurred. These findings suggest the design of clinical trials that include concomitant inhibition of EGFR downstream signaling together with direct inhibition of the EGFR receptor. Considering that panitumumab seems to be ineffective on a subset of the newly discovered mutations, drugs inhibiting EGFR through different mechanism will also be needed.

Our results have implications for the care of patients as they support the necessity of reassessing the molecular landscape of

tumors after progression to anti-EGFR drugs, which currently is not routinely done in clinical practice. The plasticity of tumor cells and their high capacity of adaptation under selective drug pressure, emphasizes the need for sequential tumor or plasma biopsies to better monitor and personalize treatment.

In summary, our study highlights the importance of reassessing the molecular profile of the overall disease burden longitudinally during therapy, and provides evidence that acquired resistance to anti-EGFR therapy in patients with mCRC arises from the emergence of heterogeneous and overlapping molecular changes. Such complexity converges on two main mechanisms of resistance: activating mutation in EGFR downstream signaling and mutations in EGFR ectodomain that disrupt antibody-receptor binding. In light of these findings, pharmacologic studies combining inhibition of both EGFR and EGFR downstream signaling effectors to bypass cetuximab resistance are warranted.

Disclosure of Potential Conflicts of Interest

A. Bardelli is a consultant/advisory board member for Biocartis, Horizon Discovery, and Trovogene. C. Montagut is a consultant/advisory board member for Merck. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: S. Arena, B. Bellosillo, A. Martinez, I. Canadas, E. Gavilan, F. Di Nicolantonio, A. Bardelli, C. Montagut

Development of methodology: B. Bellosillo, G. Siravegna, A. Martinez, I. Canadas, E. Gavilan, A. Dalmases, A. Rovira, F. Di Nicolantonio, A. Bardelli, C. Montagut

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): G. Siravegna, A. Martinez, I. Canadas, S. Misale, I. Gonzalez, M. Iglesias, E. Gavilan, S. Hobor, J. Sanchez, A. Dalmases, J. Bellmunt, J. Albanell, C. Montagut

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Arena, B. Bellosillo, G. Siravegna, A. Martinez, I. Canadas, N. Ferruz, E. Gavilan, G. Corti, S. Hobor, G. Crisafulli, M. Salido, J. Sanchez, A. Dalmases, J. Bellmunt, J. Albanell, A. Bardelli, C. Montagut

Writing, review, and/or revision of the manuscript: S. Arena, B. Bellosillo, G. Siravegna, A. Martinez, I. Canadas, S. Misale, E. Gavilan, A. Dalmases, J. Bellmunt, F. Di Nicolantonio, J. Albanell, A. Bardelli, C. Montagut

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A. Rovira, C. Montagut

Study supervision: A. Dalmases, F. Di Nicolantonio, J. Albanell, A. Bardelli, C. Montagut

Other (generation of cetuximab-resistant cell lines): L. Lazzari, M. Russo

Other (designed and analyzed the modeling work): G. De Fabritiis

Acknowledgments

The authors thank Dr. Salvatore Siena, Dr. Andrea Sartore Bianchi, and members of the laboratory of Molecular Genetics for critical reading and editing of this article. The authors also thank Fundació Cellex (Barcelona) for a generous donation to the Hospital del Mar Medical Oncology Service.

Grant Support

This work was supported by RD12/0036/0051, PI12/00989, PI12/00680, PT13/0010/0005, 2014 SGR 567 and 2014 SGR 740 grants and by the Xarxa de Banc de Tumors de Catalunya (to C. Montagut). The European Community's Seventh Framework Programme under grant agreement no. 259015 COLTHERES (to A. Bardelli); Associazione Italiana per la Ricerca sul Cancro (AIRC) IG grant no. 12812 (to A. Bardelli); AIRC MFAG no. 11349 (to F. Di Nicolantonio); grant DFarmacogenomica||—5 per mille 2009 MIUR—Fondazione Piemontese per la Ricerca sul Cancro—ONLUS (to F. Di Nicolantonio); AIRC 2010 Special Program Molecular Clinical Oncology 5 per mille, project no. 9970 (to A. Bardelli); FPRC 5 per mille 2010 and 2011 Ministero della Salute (to A. Bardelli); Ministero dell'Istruzione, dell'Università e della Ricerca, progetto PRIN 2010-2011 (to A. Bardelli). J. Albanell is a recipient of intensification program ISCI/FEDER.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 5, 2014; revised December 19, 2014; accepted January 8, 2015; published OnlineFirst January 26, 2015.

References

- Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med* 2008;359:1757–65.
- Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* 2008;26:1626–34.
- Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 2009;360:1408–17.
- Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. *J Clin Oncol* 2010;28:4706–13.
- Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. *J Clin Oncol* 2010;28:4697–705.
- Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. *Nature* 2012;486:532–6.
- Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. *Nature* 2012;486:537–40.
- Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med* 2014;6:224ra24.
- Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. *Sci Transl Med* 2014;6:224ra26.
- Morelli MP, Overman MJ, Dasari A, Kazmi SMA, Vilar Sanchez E, Eng C, et al. Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies. *J Clin Oncol* 31, 2013 (suppl; abstr 3512).
- Newhall K, Price T, Peeters M, Kim TW, Li J, Cascinu S, et al. Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from metastatic colorectal cancer patients treated with panitumumab or cetuximab monotherapy. *Ann Oncol* 2014;25:Suppl 2:ii105–17.
- Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. *Nat Med* 2012;18:221–3.
- Buch I, Ferruz N, De Fabritiis G. Computational modeling of an epidermal growth factor receptor single-mutation resistance to cetuximab in colorectal cancer treatment. *J Chem Inf Model* 2013;53:3123–6.
- Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. *Sci Transl Med* 2011;3:99ra86.
- Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. *Cancer Discov* 2013;3:658–73.
- Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multi-region sequencing. *N Engl J Med* 2012;366:883–92.
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228–47.
- Whitehead RH, Macrae FA, St John DJ, Ma J. A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. *J Natl Cancer Inst* 1985;74:759–65.
- Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. *Cancer Cell* 2005;7:301–11.
- Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. Comparison of multiple Amber force fields and development of improved protein backbone parameters. *Proteins* 2006;65:712–25.
- Harvey MJ, Giupponi G, Fabritiis GD. ACEMD: accelerating biomolecular dynamics in the microsecond time scale. *J Chem Theory Comput* 2009;9:1632–9.
- Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. *Cancer Discov*;4:1269–80.

Arena et al.

23. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. *Nat Med* 2008;14:985–90.
24. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med* 2011;3:75ra26.
25. Voigt M, Braig F, Gothel M, Schulte A, Lamszus K, Bokemeyer C, et al. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. *Neoplasia* 2012;14:1023–31.
26. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. *Br J Cancer* 2009;101:715–21.
27. Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, Huang J, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. *Clin Cancer Res* 2013;19:1902–12.
28. Troiani T, Napolitano S, Vitagliano D, Morgillo F, Capasso A, Sforza V, et al. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. *Clin Cancer Res* 2013;20:3775–86.
29. Hobor S, Van Emburgh BO, Crowley E, Misale S, Di Nicolantonio F, Bardelli A. TGF- α and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells. *Clin Cancer Res* 2014;20:6429–38.